During Q4 earnings calls, biopharmaceutical companies reflected on the cumulative impact of the COVID-19 pandemic. An assessment of US-based physician sentiment (n=62) provides a useful ‘on-the-ground’ perspective to further examine these issues.

On International Women's Day, ZoomRxers #ChooseToChallenge any gender bias at the workplace. We commit to bringing about change and accelerating gender parity at the workplace.

Across multiple indications, physicians anticipate 2021 will be an exciting year for advancing treatments across autoimmune and auto-inflammatory conditions.In a study conducted by ZoomRx late December 2020, 107 practicing U.S. rheumatologists

Early stage data showcasing the potential of both genome editing using CRISPR and gene therapy in non-malignant hematological disorders captured attention during this year’s fully virtual ASH annual meeting.A highlight of

Andrew Yukawa is a Consultant in our San Francisco office. His willingness to both learn from his teammates and his generosity in sharing his own skills have made him a key member of

Uma Sankar is a Software Development Lead in our Chennai office. She’s been at ZoomRx for over four years and has worked in software development for seven. Uma’s deep understanding of

Oncologists are growing accustomed to attending the field’s major meetings virtually, with AACR, ASCO, and now ESMO 2020 having gone fully digital.While the virtual format has undoubtedly impacted attendees’ experiences and

The prostate-specific antigen (PSA) score has become a critical post-diagnosis tool for oncologists as they discuss prostate cancer disease state with their patients along with their families and caregivers.Oncologist-patient relationships are based

A return to pre-pandemic levels of in-person promotional activity looks increasingly uncertain in H2 2020. Given this uncertainty, pharmaceutical manufacturers, from diversified, multinational firms to more focused, growth-stage companies are navigating the complexities

Despite the disruption and transition to a completely virtual format, 2020 was not an off-year for ASCO. Nearly all oncologists who attended this year’s ASCO Annual Meeting felt that it represented at

Pharmaceutical manufacturers, from diversified, multinational firms to focused, growth-stage companies are adapting to the reality of COVID-19. Recent Q1 investor calls provide insight into both the impact of the pandemic thus far on

Often, traditional research doesn't answer all questions pertaining to clinical treatment decisions. Here's ZoomRx's new approach to address such questions.

Since 2018, the migraine treatment landscape has changed dramatically, with two new approvals in the month of February alone (Vyepti, Nurtec ODT). In light of these developments, we were curious about how migraine